Skip to content

InMed Pharmaceuticals Inc.

MTRI· NasdaqCore metricsCIK 1728328

Pharmaceutical preparations553 peers

Filings
536
Raw facts
6,570
Metric values
2,009
$820.19K
Q2 2026+7.5% FY25 yoy
-$2.33M
Q1 2027N/M FY26 yoy
-$2.54M
Q1 2024N/M FY23 yoy
-$8.10M
—derivedN/M FY24 yoy
-$0.42
Q1 2027N/M FY26 yoy
$1.09M
Q1 2027−79.6% FY26 yoy

Financials

Revenue

$4.94MFY 2025
$4.94M0FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-06-30$4,942,633reported
FY 20242024-06-30$4,597,730reported
FY 20232023-06-30$4,135,561reported
FY 20222022-06-30$1,365,755 revisedreported
FY 20212021-06-30$1,904,013reported

Segments

Segments
Operating income by Segments, FY2022 to FY2023FY2022FY2023
LineFY2023ShareChange
BayMedica-$1.21M—N/M
InMed-$6.74M—N/M
Total-$7.95M

From the 10-K filed Sep 29, 2023MTRI

Pharmaceutical preparations

InMed Pharmaceuticals Inc. is the 484th largest of the 554 covered companies the SEC files under this code, by total assets. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in total assets first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

InMed Pharmaceuticals Inc. · CIK 1728328 · Engraved from SEC EDGAR